Vertex Pharmaceuticals has multiple growth drivers with potentially more on the way. Yo-yos are fun for kids. But yo-yo stock ...

What should investors who are experiencing Nasdaq market whiplash do now? I think buying three Nasdaq stocks hand over fist and holding them for decades is a smart move.

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here. Markets had a difficult start to 2025; ...

The Value Fund finished Q1 +3.0% net of fees and expenses. Markets had a challenging start to 2025, with elevated volatility across the major indices. The top contributor to the portfolio in Q1 was ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma ...

With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

Which group of individuals is in the best position to spot early warning signs of economic trouble? There's a good case to be ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.